Skip to main content .
aspr U.S. Department of Health & Human Services
  Public Health Emergency
BARDA Stakeholder Portal  
EXPANDING PHARMACEUTICAL MANUFACTURING IN THE UNITED STATES Support Services MCM Manufacturing Clinical Trials
BARDA’s Expanding
COVID-19 Medical Countermeasure Portfolio

BARDA has a proven track record of responding to pandemics and developing lifesaving medical countermeasures. We are rapidly executing new partnerships and building a robust COVID-19 MCM Portfolio because Americans deserve to have safe, effective medical products.

Envelope icon Follow Us

Be the first to get updated on the progress of BARDA Portfolio Partners. Sign-up for our email announcements:

BARDA JUMP-STARTED COVID-19 TESTS

BARDA scientists started working with private-sector partners in January 2020, days after the novel coronavirus was first reported.

BARDA continues to support test development and has expanded support of programs that increase testing speed and capacity for lab tests, as well as broaden access to testing by developing point-of-care and home-use platforms.

Doing Business with BARDA

BARDA BAA: COVID-19 Areas of Interest

BARDA is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcement (BAA-18-100-SOL-00003).

Learn More

Doing Business with BARDA

Novel Coronavirus EZ-BAA

To spur innovation, BARDA has issued its business-friendly, streamlined Easy Broad Agency Announcement (EZ-BAA) to support a number of new medical countermeasures to fight the COVID-19 outbreak.

Learn More

Doing Business with BARDA

2019 Novel Coronavirus Federal Market Research Initiative

If you are interested in partnering with the federal government on a COVID-19 medical countermeasure, submit your ideas to a platform that reaches a host of potential federal partners!

Learn More